Paracetamol (Acetaminophen) tablets

Paracetamol (Acetaminophen) tablets

Form: Oral Tablets

Strength: 500 mg, 650 mg, 1000 mg (US), 500 mg

Reference Brands: Tylenol(US)

Category: Analgesic

Paracetamol (Acetaminophen) is widely approved in the EU and US for pain and fever relief. In the EU, brands like Panadol are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing quality. In the US, FDA approval is based on extensive clinical data, with numerous generic options available. Both regions require detailed dossiers for initial approval and continuous pharmacovigilance. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support efficient market access for paracetamol, ensuring adherence to European and American standards for safe, effective analgesic and antipyretic therapy, helping you navigate complex regulatory landscapes seamlessly.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Dexketoprofen + Tramadol tablets

Strength: 25 mg dexketoprofen + 37.5 mg tramadol

Form: Tablets

Reference Brands: Enantyum(EU)

View Details Get Enquiry
Paracetamol + Codeine tablets

Strength: 300 mg paracetamol + 30 mg codeine; 300 mg + 60 mg

Form: Tablets

Reference Brands: Tylenol with Codeine(US)

View Details Get Enquiry
Aceclofenac + Paracetamol tablets

Strength: 100 mg Aceclofenac + 325 mg Paracetamol

Form: Tablets

Reference Brands: Generic formulations marketed under different names

View Details Get Enquiry
Tramadol + Paracetamol tablets

Strength: 37.5 mg tramadol + 325 mg paracetamol; 75 mg + 650 mg

Form: Oral Tablets

Reference Brands: Ultracet(US); Tramacet(EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

We use cookies to ensure you get the best experience. Learn more